A Review of CBT Treatments for Substance Use Disorders

Morin, Jean-François G.; Harris, Maggie W.; Conrod, Patricia J.

doi:10.1093/oxfordhb/9780199935291.013.57

Cited by 11 publications

(6 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CBT is a technique that is also utilised in motivational approaches. It is a directive and dominant paradigm 21 that aims at changing maladaptive attitudes, beliefs and cognition as elements of behaviour that are considered psychological intrusions 22 . It is more effective in sustaining and improving behavioural changes tailored to the client's situation when providing cognitivebehavioural strategies, such as cognitive restructuring, problem-solving skills, and self-monitoring 23 .…”

Section: Introductionmentioning

confidence: 99%

The leading role of evidence-based practices in the treatment of patients with substance use disorders: a systematic review

et al. 2023

View full text Add to dashboard Cite

Objectives: To explore the effectiveness of motivational interviewing, motivational enhancement therapy, and cognitive behaviour therapy for patients with substance use disorders, and to estimate the effect of such comparison in patient care setting. Method: The systematic review was conducted from September 2021 to February 2022, and comprised search on MEDLINE, EMBASE, Web of Science, PsycINFO, Google Scholar, Science Direct, PubMed, Clinical Trials.gov and OvidSP databases for experimental studies and randomised controlled trials related to substance use disorders published in peer-reviewed English-language journals between 2001 and 2021. Quality of the studies was assessed using the Modified Cochrane Collaboration risk of the bias assessment criteria. Results: Of the 314 studies initially identified, 41(13%) were subjected to full-text assessment, and, of them, 16(39%) were reviewed and analysed. There were 8(50%) studies done is the United States, 4(25%) in the United Kingdom, and 1(6.25%) each in Germany, Australia, South Korea and South Africa. All the 16(100%) studies were intervention-based, with 6(37.5%) being randomised controlled trials. There were 8(50%) studies using motivational interviewing and cognitive behaviour therapy, 5(31.25%) had significant results with a combination of motivational enhancement therapy and cognitive behaviour therapy, 3(18.75%) supported motivational enhancement therapy and cognitive behaviour therapy in combination, and 2(12.5%) studies combined motivational interviewing, motivational enhancement therapy and cognitive behaviour therapy, reporting significant results while simultaneously addressing multiple patient variables. Conclusion: All studies were heterogeneous. Motivational interviewing produced short-term treatment outcomes and played a supportive role in sustaining motivation. ---Continue

show abstract

Section: Introductionmentioning

confidence: 99%

The leading role of evidence-based practices in the treatment of patients with substance use disorders: a systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This study also underlines the interest of developing intervention targeting the tendency to smoke mostly alone in youth, for both prevention and treatment of cannabis use problems. One example could be cognitive-behavioral therapies (CBT), which have already been shown to be effective for depression (Hofmann et al, 2012) and substance use disorders (Morin et al, 2017, McHugh et al, 2010, in conjunction with interpersonal psychotherapy (IPT), as proposed by older studies (Brache, 2012), and which addresses interpersonal deficits, including social isolation (Cuijpers et al, 2011). Those protocols adapted to cannabis-using patients could teach them to identify the mechanisms that led them to isolate themselves and the suffering that accompanies it while highlighting their concrete difficulties related to cannabis use in order to develop better habits, reintegrate into social situations, and reduce their consumption.…”

Section: Discussionmentioning

confidence: 99%

Smoking Mostly Alone as a Risk Factor for Cannabis Use Disorders and Depressive Symptoms

Chassagne

Raynal

Bronchain

et al. 2022

Int J Ment Health Addiction

View full text Add to dashboard Cite

The empirically grounded etiological models of cannabis use already include a vast range of psychological factors (within an individual), paving the ground for individualized prevention and intervention programs. However, the interpersonal (among individuals) and relational variables influencing the emergence of excessive cannabis use are less understood. Particularly, the impact of consumption context (i.e., smoking alone or with others) on cannabis use intensity in youth remains to be clarified. We evaluated how smoking mostly alone modulates cannabis use disorders (CUD) and depressive symptoms in college students. A sample of 854 individuals from France (568 women, 286 men) who used cannabis in the last 6 months completed self-report questionnaires evaluating cannabis consumption, CUD symptoms, and depressive symptoms. Mostly alone users presented higher current use frequency as well as increased CUD and depressive symptoms compared to mostly social users. Smoking mostly alone remained positively correlated with CUD and depressive symptoms, even when controlling for current use frequency. The association between smoking mostly alone and depressive symptoms was significant before adjustment for symptoms of CUD. The loss of significance of this association after control reflected the mediating effects of symptoms of CUD on the relationship between smoking mostly alone and depressive symptoms. These results suggest that smoking mostly alone constitutes a risk factor for uncontrolled cannabis use and promote the relationship between cannabis use and depressive disorders, potentially through loneliness and social isolation. Longitudinal studies are required to identify the causal mechanisms underlying the links between smoking mostly alone, cannabis use and psychopathological disorders.

show abstract

“…Research on CBT for substance use disorder has predominantly examined effects of CBT on substance use abstinence, not MOUD adherence. CBT provides individuals with strategies designed to help the patient identify highrisk situations and triggers and to promote the use of effective coping strategies to avoid substance use in highrisk situations [19][20][21]. In a review of adjunctive CBT intervention for those in buprenorphine treatment [22], only 11 RCTs were identified, and evidence from the low risk of bias studies therein indicated that adding psychosocial interventions to buprenorphine treatment does not significantly improve substance use outcomes.…”

Section: Cognitive Behavioral Therapymentioning

confidence: 99%

Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder

Peter

Murphy

Witkiewitz

et al. 2023

Trials

View full text Add to dashboard Cite

Background Buprenorphine-naloxone is a medication shown to improve outcomes for individuals seeking treatment for opioid use disorder (OUD); however, outcomes are limited by low medication adherence rates. This is especially true during the early stages of treatment. Methods The present study proposes to utilize a sequential multiple assignment randomized trial design to compare two psychological interventions targeting buprenorphine-naloxone adherence: (1) contingency management (CM) and (2) brief motivational interviewing plus substance-free activities session plus mindfulness (BSM). Participants will be N = 280 adults who present to a university-based addictions clinic seeking treatment for OUD. Participants will be randomized to condition to receive 4 sessions of their assigned intervention (CM or BSM). Participants who are adherent, defined as attending physician appointments and having buprenorphine present in urine toxicology, will enter maintenance intervention for an additional 6 months. Those who are not adherent will be re-randomized to receive either the other intervention or both interventions. Follow-up will occur at 8 months post-randomization. Conclusions This novel design will examine the benefit of sequential treatment decisions following non-adherence. The primary outcome of this study is buprenorphine-naloxone medication adherence, as assessed by physician visit attendance and presence of buprenorphine in urine. Results will elicit the relative efficacy of CM and BSM compared to one another and whether keeping the initial treatment approach when adding the alternative approach for initially non-adherent individuals is beneficial. Trial registration ClinicalTrials.gov NCT04080180

show abstract

A Review of CBT Treatments for Substance Use Disorders

Cited by 11 publications

References 65 publications

The leading role of evidence-based practices in the treatment of patients with substance use disorders: a systematic review

The leading role of evidence-based practices in the treatment of patients with substance use disorders: a systematic review

Smoking Mostly Alone as a Risk Factor for Cannabis Use Disorders and Depressive Symptoms

Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder

Contact Info

Product

Resources

About